#Obesity medicine
Chronic weight management as a clinical specialty.
Crunchometer: open-source feeding analysis
An open-source acoustic device for mice detects semaglutide appetite suppression and maps meal-tracking neurons in the lateral hypothalamus.
GLP-1 cancer risk vs bariatric surgery
A July 2026 study found GLP-1 receptor agonists were tied to lower colorectal and pancreatic cancer rates than bariatric surgery, not higher.
CRAVE study: GLP-1, food cravings, and diet
The CRAVE study tracked 28 adults on GLP-1 agonists for 24 weeks. Weight fell, diet quality did not improve, and micronutrient intake dropped.
The obesity drug pipeline in 2026
A 2026 JCEM review maps next-generation obesity drugs, from approved dual agonists to triple agonists like retatrutide still in Phase 3.
Tirzepatide: PERCEPTIONS survey findings
The PERCEPTIONS survey (n=518, US) found health improvement was the top reason patients started tirzepatide; cost and insurance were the main barriers.
GLP-1 drugs: fewer falls in older adults
Semaglutide and tirzepatide were associated with roughly half the femoral fracture rate versus DPP-4 inhibitors in older adults with type 2 diabetes.
Tirzepatide vs semaglutide: JASSO subgroup
SURMOUNT-5 subgroup: tirzepatide cut body weight by 20.1% vs 12.9% for semaglutide in 383 adults meeting Japan obesity disease criteria.
Why Dr. Reddy's paused generic semaglutide
Dr. Reddy's paused generic semaglutide after flagging an API quality issue. Here is what that means for patients, prescribers, and the generic GLP-1 market.
GLP-1 drugs and US military adherence
A Military Health System study of 10,649 service members found tirzepatide led on adherence and persistence. Male members discontinued more often than females.
GLP-1 drugs and older adults: key evidence
A 2026 review covers tirzepatide, semaglutide, and liraglutide in older patients with obesity and type 2 diabetes, and where evidence has gaps.
GLP-1 drugs: psychiatric safety in 2026
Tirzepatide and semaglutide show comparable psychiatric profiles. Semaglutide beats older GLP-1 agents on depression and anxiety.
GLP-1 persistence in the US military
A 10,649-patient Military Health System database study found tirzepatide had 81.9% one-year persistence vs 70.7% for semaglutide and 34.2% for liraglutide.